legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities.
Segment Assets––
We manage our assets on a total company basis, not by operating segment, as our operating assets are shared or commingled. Therefore, our CODM does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were $
213
billion as of December 31, 2024 and $
227
billion as of December 31, 2023.
Selected Statement of Operations Information
(a)
Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss).
As described above, in connection with the organizational changes effective in the first quarter of 2024, overhead costs associated with our manufacturing operations and costs associated with R&D and medical and safety activities managed by our global ORD and PRD organizations as they operated in 2024 are included in Biopharma’s earnings. We have reclassified $
14.7
billion and $
9.2
billion of net costs in 2023 and 2022, respectively, from Other business activities to Biopharma to conform to the current period presentation.
(b)
Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. As described above, in connection with the organizational changes effective in the first quarter of 2024, we have reclassified $
331
million and $
294
million of net costs in 2023 and 2022, respectively, from Other business activities to Biopharma to conform to the current period presentation.
(c)
Biopharma’s revenues and earnings in 2024 reflect a non-cash favorable product return adjustment of $
771
million recorded in the first quarter of 2024 and in 2023 reflected a non-cash revenue reversal of $
3.5
billion (see
Note 17C
). In 2023, Biopharma earnings included approximately $
6.2
billion of inventory write-offs and related charges to
Cost of sales
mainly due to lower-than-expected demand for our COVID-19 products. In 2022, Biopharma earnings included COVID-19-related charges of approximately $
1.7
billion to
Cost of sales
, composed of (i) inventory write-offs of approximately $
1.2
billion related to COVID-19
Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
products that exceeded or were expected to exceed their approved shelf-lives prior to being used and (ii) charges of approximately $
0.5
billion, primarily related to excess raw materials for Paxlovid. Biopharma’s earnings also include dividend income from our investment in ViiV of $
272
million in 2024, $
265
million in 2023 and $
314
million in 2022.
(d)
Other business activities include revenues and costs associated with PC1 and Pfizer Ignite as well as costs that we do not allocate to our operating segments, per above.
(e)
Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). Earnings in